Story perspectives
CRISPR's Casgevy Launch Promises Major Revenue Growth
8/30/2025
50 10
1 of 1
Story summary
- CRISPR Therapeutics has commercialized Casgevy, a CRISPR-based gene-editing therapy for sickle cell disease and beta-thalassemia.
- The company is developing in vivo therapies for conditions like heart disease.
- Analysts anticipate substantial revenue growth from Casgevy and a positive market outlook for CRISPR therapies.
- CRISPR holds a strong market position despite competition and early-stage pipeline risks.
